abatacept
Orencia
Pharmaceutical company: Bristol-Myers Squibb
NEW INDICATION & DOSAGE
Active psoriatic arthritis
Children age 2 and older weighing 50 kg or more: 125 mg subcut once weekly without an IV loading dose.
Children age 2 and older weighing 25 to less than 50 kg: 87.5 mg subcut once weekly without an IV loading dose.
Children age 2 and older weighing 10 to less than 25 kg: 50 mg subcut once weekly without an IV loading dose.
Released: January 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer
enzalutamide
Xtandi
Pharmaceutical company: Astellas Pharma
NEW INDICATION & DOSAGE
Nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis
Adults: 160 mg PO once daily until disease progression or unacceptable toxicity occurs, with or without a gonadotropin-releasing hormone analog.
Adjust-a-dose: Suspend treatment after 36 weeks of therapy if prostate-specific antigen (PSA) is undetectable (less than 2 ng/mL). Restart treatment when PSA has increased to 2 ng/ML or more for patients who had prior radical prostatectomy, or 5 ng/mL or more for patients who had prior primary radiation therapy.
Released: January 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer
infliximab-dyyb
Zymfentra
Pharmaceutical company: Celltrion, Inc.
NEW FORMULATION
Subcut injection: 120 mg/mL prefilled syringe or pen.
NEW INDICATION & DOSAGE
Maintenance of moderately to severely active ulcerative colitis after initial treatment with IV infliximab product
Adults: Patients responding to maintenance therapy with IV infliximab product, give first subcut dose in place of the next scheduled IV infusion. Week 10 and thereafter, give 120 mg subcut once every two weeks.
Maintenance of moderately to severely active Crohn disease after initial treatment with IV infliximab product
Adults: Patients responding to maintenance therapy with IV infliximab product, give first subcut dose in place of the next scheduled IV infusion. Week 10 and thereafter, give 120 mg subcut once every two weeks.
Released: January 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer
ivosidenib
Tibsovo
Pharmaceutical company: Servier Pharmaceuticals
NEW INDICATION & DOSAGE
Relapsed or refractory myelodysplastic syndromes
Adults: 500 mg PO once daily. Treat for a minimum of 6 months to allow time for clinical response or until disease progression or unacceptable toxicity occurs.
Released: January 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer
pembrolizumab
Keytruda
Pharmaceutical company: Merck
NEW INDICATION & DOSAGE
Advanced or metastatic biliary tract cancer in combination with gemcitabine and cisplatin
Adults 200-mg IV infusion every 3 weeks or 400-mg IV infusion every 6 weeks until disease progression, unacceptable toxicity occurs, or up to 24 months. Give before chemotherapy when given the same day.
First-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma, in combination with fluoropyrimidine- and platinum-containing chemotherapy
Adults: 200-mg IV infusion every 3 weeks or 400-mg IV infusion every 6 weeks until disease progression, unacceptable toxicity occurs, or up to 24 months. Give before chemotherapy when given on the same day.
Released: January 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer
secukinumab
Cosentyx
Pharmaceutical company: Novartis
NEW INDICATION & DOSAGE
Moderate to severe hidradenitis suppurativa
Adults: 300 mg subcut at weeks 0,1,2,3, and 4; then every 4 weeks thereafter. If inadequate response, may increase to 300 mg every 2 weeks.
Released: January 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer
tirzepatide
Zepbound
Pharmaceutical company: Eli Lilly and Company
NEW INDICATION & DOSAGE
Adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (for example, hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease) (Zepbound only)
Adults: Initially, 2.5 mg subcut once weekly for 4 weeks, then increase to 5 mg. May increase in 2.5-mg increments after at least 4 weeks at the current dose. The recommended maintenance dosage is 5 mg, 10 mg, or 15 mg once weekly based on response and tolerability.
Released: January 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer